Clinical Trial Update: Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the best sequence of EGFR-TKI therapy in NSCLC with EGFR mutations; status not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Fondazione Ricerca Traslazionale | Conditions: NSCLC | Phase 2 | Status: UNKNOWN